<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00176423</url>
  </required_header>
  <id_info>
    <org_study_id>01T-411</org_study_id>
    <nct_id>NCT00176423</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia</brief_title>
  <official_title>Adjunctive Galantamine for Treatment of Cognitive Impairments in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ortho-McNeil Neurologics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether adjunctive galantamine is effective in the&#xD;
      treatment of cognitive impairments in patients with schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with schizophrenia are characterized by a broad range of neurocognitive&#xD;
      abnormalities. These include impairments in attention; eye-tracking; visual and verbal&#xD;
      memory; working memory; processing speed; and sensory gating, as measured by P50. These&#xD;
      impairments are major determinants of poor functional outcome in patients with schizophrenia.&#xD;
      Conventional antipsychotics have limited effects on these impairments. Second generation&#xD;
      antipsychotics (SGAs) may have modest benefits for cognitive function, but whether this&#xD;
      represents a direct cognitive enhancing effect has not been established. Regardless, patients&#xD;
      continue to exhibit pronounced cognitive impairments despite adequate new generation&#xD;
      antipsychotic treatment. Adjunctive pharmacotherapy may offer a viable approach for the&#xD;
      treatment of cognitive impairments. Adjunctive agents can be used to modulate specific&#xD;
      neurotransmitter systems that are hypothesized to be involved in the pharmacology of&#xD;
      cognitive functions.&#xD;
&#xD;
      Acetylcholine acts at muscarinic and nicotinic cholinergic receptors. These receptors are&#xD;
      broadly distributed through the brain, including the neocortex, hippocampus, and basal&#xD;
      ganglia. Cholinergic mechanisms have been implicated in the regulation of attention, memory,&#xD;
      processing speed, and sensory gating processes; processes which are impaired in patients with&#xD;
      schizophrenia. Nicotine has previously been shown to improve sensory gating, as measured by&#xD;
      P50, and eye-tracking in patients with schizophrenia. The gene for the alpha-7 nicotinic&#xD;
      receptor, which is hypothesized to be the nicotinic receptor involved in sensory gating&#xD;
      regulation, has also been shown to be linked to schizophrenia.&#xD;
&#xD;
      Galantamine (Trade name: Reminyl) is a new FDA-approved selective acetylcholinesterase&#xD;
      inhibitor (AChEI), which may also allosterically modulate nicotinic receptors, enhance&#xD;
      receptor sensitivity, and increase nicotinic receptor density. Galantamine is marketed by&#xD;
      Janssen Research Foundation. In animal models of aging, galantamine enhanced long-term&#xD;
      potentiation, ameliorated learning impairments, and elevated the number of nicotinic&#xD;
      receptors in the hippocampus and neocortex. In placebo-controlled studies, galantamine has&#xD;
      been shown to not only delay deterioration but to improve cognitive function in patients with&#xD;
      Alzheimer's disease. There is also preliminary evidence that galantamine may ameliorate&#xD;
      positive psychotic symptoms in these patients.&#xD;
&#xD;
      AChEIs have not been extensively studied in patients with schizophrenia. We have conducted a&#xD;
      6-week open-labeled pilot study of adjunctive donepezil in patients treated with olanzapine&#xD;
      for a minimum of 6 months. Fifteen patients entered the study and 14 patients completed the&#xD;
      study. One patient withdrew with a complaint of sedation. The demographic characteristics of&#xD;
      the patients who completed the study were: mean (SD) age: 43.1 6.6; 71% male; 78% caucasian;&#xD;
      and mean (SD) duration of illness: 24.7 7.2. The mean (SD) olanzapine dose was 25.7 11.9&#xD;
      mg/day. Two patients were receiving benzodiazepines, two were receiving antidepressants, and&#xD;
      one was receiving valproic acid. Donepezil resulted in a modest improvement in sensory&#xD;
      gating. Nine patients had abnormal P50 at baseline, which normalized for five patients&#xD;
      following treatment. Donepezil had a more pronounced effect on neuropsychological test&#xD;
      performance, with large and significant effect sizes observed for the visual memory (effect&#xD;
      size (ES)=.57) and manual dexterity (ES=.93) measures. There were moderate improvements on&#xD;
      the verbal recall memory (ES=0.46) and processing speed (ES=0.48) measures. The only&#xD;
      cognitive measure that did not change with treatment was a measure of attention. There were&#xD;
      no significant changes in either positive symptom (mean (SD), baseline: 9.3 3.8; week 6: 8.2&#xD;
      3.8; t=-1.55, df=14, p=.14) or negative symptom (mean(SD), baseline: 29.7 10.9; week 6: 30.0&#xD;
      12.6; t=0.15, df=14, p=.88) measures.&#xD;
&#xD;
      The results of this study suggest that adjunctive AChEIs may be an effective treatment for&#xD;
      cognitive impairments in patients with schizophrenia. Moderate to large effect size&#xD;
      improvements were observed on verbal and visual memory, processing speed, and manual&#xD;
      dexterity measures. Patients exhibited a greater than 20% increase in suppression of their&#xD;
      P50 response to repeated auditory stimuli. There was no effect of donepezil on a measure of&#xD;
      attention. Donepezil was well tolerated; only one patient dropped out of the study and nine&#xD;
      of the remaining subjects chose to continue on the drug beyond the protocol. An important&#xD;
      aspect of the study was that cognitive function improvement occurred in the context of&#xD;
      concurrent olanzapine treatment, which is reported to improve P50 and cognitive function&#xD;
      (Purdon et al, 2000; Light et al, 2000). Thus, donepezil was able to further enhance&#xD;
      cognitive function in patients who may have already benefitted from olanzapine treatment.&#xD;
&#xD;
      The primary study objectives are:&#xD;
&#xD;
        1. To examine whether adjunctive galantamine is more effective than placebo for&#xD;
           neuropsychological measures of attention, verbal and visual memory, working memory,&#xD;
           processing speed, and manual dexterity.&#xD;
&#xD;
        2. To examine whether adjunctive galantamine is more effective than placebo for evoked&#xD;
           potential measures of sensory gating (i.e., P50) and attention (i.e., P300 and Gamma&#xD;
           Band Response (GBR)) and smooth pursuit eye movement.&#xD;
&#xD;
      We hypothesize that galantamine will have a significant benefit for these cognitive behaviors&#xD;
      based on the role of acetylcholine in the regulation of these behaviors; our pilot study with&#xD;
      donepezil which demonstrated that AChEIs may have a beneficial effect for verbal and visual&#xD;
      memory, processing speed, and manual dexterity; and previous studies that have shown acute&#xD;
      nicotine administration to normalize P50 and eye-tracking in patients with schizophrenia.&#xD;
&#xD;
      The secondary study objectives are:&#xD;
&#xD;
        1. To examine whether adjunctive galantamine is more effective than placebo for positive&#xD;
           symptoms and negative symptom measures.&#xD;
&#xD;
        2. To examine whether adjunctive galantamine is more likely than placebo to cause nausea,&#xD;
           vomiting, diarrhea, anorexia, weight loss, or dizziness, i.e., common side effects&#xD;
           associated with AChEI treatment.&#xD;
&#xD;
        3. To examine whether galantamine is more likely than placebo to cause an increase in&#xD;
           either extrapyramidal symptoms or dyskinetic movements.&#xD;
&#xD;
        4. To examine whether galantamine is more effective than placebo for reducing smoking&#xD;
           behavior.&#xD;
&#xD;
      We hypothesize that there will not be a significant difference between galantamine and&#xD;
      placebo for positive and negative symptoms based on our donepezil pilot study. We hypothesize&#xD;
      that galantamine will be associated with an increased incidence of AChEI associated side&#xD;
      effects. We hypothesize that there will not be a significant difference between galantamine&#xD;
      and placebo for either extrapyramidal symptoms or dyskinetic movements.&#xD;
&#xD;
      Study Design and Methods: The proposed study is a randomized, parallel group, double-blind&#xD;
      comparison of adjunctive galantamine or placebo. The sample will consist of 90 clinically&#xD;
      stable inpatients and outpatients with DSM-IV schizophrenia or schizoaffective disorder.&#xD;
      There will be a 2-week stabilization phase, a 12-week treatment phase, and an optional&#xD;
      6-month open-label phase. In the 2-week stabilization phase, patients will undergo baseline&#xD;
      symptom, medical, safety, antipsychotic level, and neurocognitive assessments. In the 12-week&#xD;
      treatment phase, patients will be randomized to either galantamine or placebo. Patients will&#xD;
      receive biweekly symptom, side effect, and vital sign assessments. At the end of study (12&#xD;
      weeks), laboratory tests, EKG, antipsychotic levels, and neurocognitive assessments will be&#xD;
      repeated. Patients will be monitored at the 3-month and 6-month points of the open-labeled&#xD;
      phase, during which they will receive laboratory tests, EKG, and side effect review. At the&#xD;
      end of the 6-month open-labeled phase, patients will again be asked to participate in symptom&#xD;
      ratings and neuropsychological tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2002</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Cognitive Improvement Z-score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants were administered an eight-test neuropsychological test battery at baseline and end-of-study. The battery included the following tests: working memory: WAIS-III Letter-Number Sequencing and Brief Assessment of Cognition in Schizophrenia Number Sequencing; verbal memory: California Verbal Learning Test (CVLT); visual memory: Brief Visuospatial Memory Test (BVMT); motor speed: Grooved Pegboard; processing speed: WAIS-III Digit Symbol and WAIS-III Symbol Search; and the Gordon Diagnostic System CPT. Alternate forms of the CVLT and BVMT were used for the two test occasions. For each neuropsychological test, participant scores were converted to z-scores: z = (score - baseline mean)/baseline SD. For the primary outcome measure, an overall composite z-score was computed from the average of the individual test z-scores. A positive z-score would reflect better performance compared to baseline; a negative z-score would reflect worse performance compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECG Changes From Baseline to 12 Weeks.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Three measures were examined: PR interval, QRS interval, and QTc interval. The three measures were derived from a standard 12-lead ECG recording.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simpson Angus Scale (SAS) Total Score</measure>
    <time_frame>12 weeks (Week 12 - Week 0)</time_frame>
    <description>The SAS total were calculated by adding scores from scales #1-#11. Each scale ranges from &quot;0=None/Normal&quot; to &quot;4=Extreme/Severe&quot;. The minimum total score is 0 and the maximum score is 44. Higher scores indicate a more severe extrapyramidal side effect rating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>12 weeks (Week 12 - Week 0)</time_frame>
    <description>Change in AIMS Total Score: Frequencies of Maximum Within-Participant Increases (worsening) from Baseline by Treatment Group. Total score calculated by adding scores from scales #1-#10. Each scale ranges from &quot;0=None&quot; to &quot;4=Severe&quot;. The minimum total AIMS score is 0 and the maximum score is 40. Higher scores indicate a more severe abnormal involuntary movement rating.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>galantamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>galantamine, 24mgs, p.o., qday</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, 3 tablets, p.o., qday</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>galantamine</intervention_name>
    <description>see arm/group description</description>
    <arm_group_label>galantamine</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. DSM-IV diagnosis of either schizophrenia or schizoaffective disorder.&#xD;
&#xD;
          2. Males and females&#xD;
&#xD;
          3. Age: 18 and 60&#xD;
&#xD;
          4. Caucasian or Non-Caucasian&#xD;
&#xD;
          5. Subjects will be currently treated with one of the following new generation&#xD;
             antipsychotics: olanzapine, risperidone, quetiapine, ziprasidone, or aripiprazole.&#xD;
&#xD;
          6. Subjects will meet a priori criteria for cognitive impairment severity. The Repeatable&#xD;
             Battery for the Assessment of Neuropsychological Status (RBANS) will be used to&#xD;
             determine the level of cognitive impairment. Patients will meet entry criteria if they&#xD;
             have a RBANS total score of 90 or less (one standard deviation below the normal&#xD;
             control mean).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of an organic brain disease&#xD;
&#xD;
          2. History of DSM-IV alcohol or substance abuse (within the last month), or DSM-IV&#xD;
             alcohol or substance dependence (within the last six months).&#xD;
&#xD;
          3. Pregnant women and women taking oral contraceptives (because of the theoretical risk&#xD;
             of breakthrough ovulation).&#xD;
&#xD;
          4. Current treatment with galantamine or other acetylcholinesterase inhibitor (e.g.&#xD;
             donepezil)&#xD;
&#xD;
          5. History of a second or third degree atrioventricular (AV) block.&#xD;
&#xD;
          6. Persons with chronic medical conditions, which are unstable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert W Buchanan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Baltimore School of Medicine, Maryland Psychiatric Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maryland Psychiatric Research Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>October 2, 2020</results_first_submitted>
  <results_first_submitted_qc>November 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 16, 2020</results_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Robert Buchanan</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>acetylcholine</keyword>
  <keyword>cognitive impairments</keyword>
  <keyword>attention</keyword>
  <keyword>processing speed</keyword>
  <keyword>sensory gating</keyword>
  <keyword>eye-tracking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The number of people who signed informed consent was &quot;117&quot;. Thirty-one participants who signed informed consent did not complete the Evaluation Phase of the study and were not randomized. Eight-six (86) participants completed the Evaluation Phase of the study and were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Galantamine</title>
          <description>galantamine, 24mgs, p.o., qday</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo, 3 tablets, p.o., qday</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Galantamine</title>
          <description>galantamine, 24mgs, p.o., qday&#xD;
galantamine: see arm/group description</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo, 3 tablets, p.o., qday&#xD;
galantamine: see arm/group description</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Cognitive Improvement Z-score</title>
        <description>Participants were administered an eight-test neuropsychological test battery at baseline and end-of-study. The battery included the following tests: working memory: WAIS-III Letter-Number Sequencing and Brief Assessment of Cognition in Schizophrenia Number Sequencing; verbal memory: California Verbal Learning Test (CVLT); visual memory: Brief Visuospatial Memory Test (BVMT); motor speed: Grooved Pegboard; processing speed: WAIS-III Digit Symbol and WAIS-III Symbol Search; and the Gordon Diagnostic System CPT. Alternate forms of the CVLT and BVMT were used for the two test occasions. For each neuropsychological test, participant scores were converted to z-scores: z = (score - baseline mean)/baseline SD. For the primary outcome measure, an overall composite z-score was computed from the average of the individual test z-scores. A positive z-score would reflect better performance compared to baseline; a negative z-score would reflect worse performance compared to baseline.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Galantamine</title>
            <description>galantamine, 24mgs, p.o., qday&#xD;
galantamine: see arm/group description</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo, 3 tablets, p.o., qday&#xD;
galantamine: see arm/group description</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Cognitive Improvement Z-score</title>
          <description>Participants were administered an eight-test neuropsychological test battery at baseline and end-of-study. The battery included the following tests: working memory: WAIS-III Letter-Number Sequencing and Brief Assessment of Cognition in Schizophrenia Number Sequencing; verbal memory: California Verbal Learning Test (CVLT); visual memory: Brief Visuospatial Memory Test (BVMT); motor speed: Grooved Pegboard; processing speed: WAIS-III Digit Symbol and WAIS-III Symbol Search; and the Gordon Diagnostic System CPT. Alternate forms of the CVLT and BVMT were used for the two test occasions. For each neuropsychological test, participant scores were converted to z-scores: z = (score - baseline mean)/baseline SD. For the primary outcome measure, an overall composite z-score was computed from the average of the individual test z-scores. A positive z-score would reflect better performance compared to baseline; a negative z-score would reflect worse performance compared to baseline.</description>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.64"/>
                    <measurement group_id="O2" value="-0.03" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.68"/>
                    <measurement group_id="O2" value="0.61" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ECG Changes From Baseline to 12 Weeks.</title>
        <description>Three measures were examined: PR interval, QRS interval, and QTc interval. The three measures were derived from a standard 12-lead ECG recording.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Galantamine</title>
            <description>galantamine, 24mgs, p.o., qday&#xD;
galantamine: see arm/group description</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo, 3 tablets, p.o., qday&#xD;
galantamine: see arm/group description</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Changes From Baseline to 12 Weeks.</title>
          <description>Three measures were examined: PR interval, QRS interval, and QTc interval. The three measures were derived from a standard 12-lead ECG recording.</description>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" spread="56.0"/>
                    <measurement group_id="O2" value="3.0" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="25.1"/>
                    <measurement group_id="O2" value="-1.6" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="28.89"/>
                    <measurement group_id="O2" value="3.03" spread="27.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Simpson Angus Scale (SAS) Total Score</title>
        <description>The SAS total were calculated by adding scores from scales #1-#11. Each scale ranges from &quot;0=None/Normal&quot; to &quot;4=Extreme/Severe&quot;. The minimum total score is 0 and the maximum score is 44. Higher scores indicate a more severe extrapyramidal side effect rating.</description>
        <time_frame>12 weeks (Week 12 - Week 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Galantamine</title>
            <description>galantamine, 24mgs, p.o., qday&#xD;
galantamine: see arm/group description</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo, 3 tablets, p.o., qday&#xD;
galantamine: see arm/group description</description>
          </group>
        </group_list>
        <measure>
          <title>Simpson Angus Scale (SAS) Total Score</title>
          <description>The SAS total were calculated by adding scores from scales #1-#11. Each scale ranges from &quot;0=None/Normal&quot; to &quot;4=Extreme/Severe&quot;. The minimum total score is 0 and the maximum score is 44. Higher scores indicate a more severe extrapyramidal side effect rating.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.8"/>
                    <measurement group_id="O2" value="1.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.8"/>
                    <measurement group_id="O2" value="1.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abnormal Involuntary Movement Scale (AIMS)</title>
        <description>Change in AIMS Total Score: Frequencies of Maximum Within-Participant Increases (worsening) from Baseline by Treatment Group. Total score calculated by adding scores from scales #1-#10. Each scale ranges from &quot;0=None&quot; to &quot;4=Severe&quot;. The minimum total AIMS score is 0 and the maximum score is 40. Higher scores indicate a more severe abnormal involuntary movement rating.</description>
        <time_frame>12 weeks (Week 12 - Week 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Galantamine</title>
            <description>galantamine, 24mgs, p.o., qday&#xD;
galantamine: see arm/group description</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo, 3 tablets, p.o., qday&#xD;
galantamine: see arm/group description</description>
          </group>
        </group_list>
        <measure>
          <title>Abnormal Involuntary Movement Scale (AIMS)</title>
          <description>Change in AIMS Total Score: Frequencies of Maximum Within-Participant Increases (worsening) from Baseline by Treatment Group. Total score calculated by adding scores from scales #1-#10. Each scale ranges from &quot;0=None&quot; to &quot;4=Severe&quot;. The minimum total AIMS score is 0 and the maximum score is 40. Higher scores indicate a more severe abnormal involuntary movement rating.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="3.1"/>
                    <measurement group_id="O2" value="2.1" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="3.0"/>
                    <measurement group_id="O2" value="1.6" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Galantamine</title>
          <description>galantamine, 24mgs, p.o., qday&#xD;
galantamine: see arm/group description</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo, 3 tablets, p.o., qday&#xD;
galantamine: see arm/group description</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalization due to pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>worsening of psychiatric symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>increased alcohol consumption</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert W. Buchanan, M.D.</name_or_title>
      <organization>Maryland Psychiatric Research Center</organization>
      <phone>410-402-7876</phone>
      <email>rbuchanan@som.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

